Sökning: onr:"swepub:oai:DiVA.org:uu-193621" > Rituximab Maintenan...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03655naa a2200481 4500 | |
001 | oai:DiVA.org:uu-193621 | |
003 | SwePub | |
008 | 130205s2012 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1936212 URI |
024 | 7 | a https://doi.org/10.1200/JCO.2012.41.94162 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Gisselbrecht, Christian4 aut |
245 | 1 0 | a Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20(+) Diffuse Large B-Cell Lymphoma :b Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma |
264 | 1 | c 2012 |
338 | a print2 rdacarrier | |
520 | a Purpose The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. Patients and Methods In total, 477 patients with CD20(+) DLBCL who were in their first relapse or refractory to initial therapy were randomly assigned to one of two salvage regimens. After three cycles of salvage chemotherapy, the responding patients received high-dose chemotherapy followed by ASCT. Then, 242 patients were randomly assigned to either rituximab every 2 months for 1 year or observation. Results After ASCT, 122 patients received rituximab, and 120 patients were observed only. The median follow-up time was 44 months. The 4-year event-free survival (EFS) rates after ASCT were 52% and 53% for the rituximab and observation groups, respectively (P=.7). Treatment with rituximab was associated with a 15% attributable risk of serious adverse events after day 100, with more deaths (six deaths v three deaths in the observation arm). Several factors affected EFS after ASCT (P<.05), including relapsed disease within 12 months (EFS: 46% v 56% for relapsed disease after 12 months), secondary age-adjusted International Prognostic Index (saaIPI) more than 1 (EFS: 37% v 61% for saaIPI < 1), and prior treatment with rituximab (EFS: 47% v 59% for no prior rituximab). A significant difference in EFS between women (63%) and men (46%) was also observed in the rituximab group. In the Cox model for maintenance, the saaIPI was a significant prognostic factor (P<.001), as was male sex (P=.01). Conclusion In relapsed DLBCL, we observed no difference between the control group and the rituximab maintenance group and do not recommend rituximab after ASCT. | |
700 | 1 | a Schmitz, Norbert4 aut |
700 | 1 | a Mounier, Nicolas4 aut |
700 | 1 | a Gill, Devinder Singh4 aut |
700 | 1 | a Linch, David C.4 aut |
700 | 1 | a Trneny, Marek4 aut |
700 | 1 | a Bosly, Andre4 aut |
700 | 1 | a Milpied, Noel J.4 aut |
700 | 1 | a Radford, John4 aut |
700 | 1 | a Ketterer, Nicolas4 aut |
700 | 1 | a Shpilberg, Ofer4 aut |
700 | 1 | a Duehrsen, Ulrich4 aut |
700 | 1 | a Hagberg, Hansu Uppsala universitet,Enheten för onkologi4 aut0 (Swepub:uu)hanshagb |
700 | 1 | a Ma, David D.4 aut |
700 | 1 | a Viardot, Andreas4 aut |
700 | 1 | a Lowenthal, Ray4 aut |
700 | 1 | a Briere, Josette4 aut |
700 | 1 | a Salles, Gilles4 aut |
700 | 1 | a Moskowitz, Craig H.4 aut |
700 | 1 | a Glass, Bertram4 aut |
710 | 2 | a Uppsala universitetb Enheten för onkologi4 org |
773 | 0 | t Journal of Clinical Oncologyg 30:36, s. 4462-4469q 30:36<4462-4469x 0732-183Xx 1527-7755 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-193621 |
856 | 4 8 | u https://doi.org/10.1200/JCO.2012.41.9416 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy